Ian R. Watson

McGill University Health Centre — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index10.6kcitations161works4.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(56), CAR-T cell therapy research(29), PARP inhibition in cancer therapy(24), Virus-based gene therapy research(20), Protein Degradation and Inhibitors(16)

Publications160 total

Metagenomics and culturomics reveal the dual role of gut microbiome in the development of immune-related toxicities and immune checkpoint inhibitors efficacy in cancer
2025Open Access
Chimeric MHC class I– and II–restricted non-self epitopes broaden antitumor T cell reactions
The Journal of Experimental Medicine·2025· 1 citedOpen Access
Deep Learning Using a Latent Attention-based Network for the HAWC Observatory
2025Open Access
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy
2025· 1 citedOpen Access
Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer
Nature Cancer·2025· 19 citedOpen Access
A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins
Journal of Medicinal Chemistry·2024· 17 citedOpen Access
Spatially mapping the single-cell immune landscapes of melanoma brain metastases using imaging mass cytometry.
Journal of Clinical Oncology·2024
A resource to enable chemical biology and drug discovery of WDR Proteins
2024Open Access
Mapping the single cell spatial immune landscapes of the melanoma microenvironment
Clinical & Experimental Metastasis·2024· 6 citedOpen Access
P2 NICE's Pathways Pilot: Incorporating Disease-Specific Reference Models Into Health Technology Assessment in England
Value in Health·2023· 1 cited
Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Nature Medicine·2023· 7 citedOpen Access
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Nature Medicine·2023· 389 cited
Deep Learning Approach for the Discovery of Tumor-Targeting Small Organic Ligands from DNA-Encoded Chemical Libraries
ACS Omega·2023· 20 citedOpen Access
A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.
Journal of Clinical Oncology·2023· 2 cited
Abstract 69: Minimally invasive brain metastases are characterized by elevated immune cell infiltrate
Cancer Research·2023
Figure S1 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023· 1 citedOpen Access
Figure S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023Open Access
Data from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023Open Access
Supplementary Figure Legends and Materials and Methods from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023Open Access
Figure S2 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Lynda Chin(9), Peter M. Siegel(8), Mathieu Lajoie(8), Meredith S. Irwin(7), Michael Ohh(7), Shivshankari Rajkumar(6), Matthew Dankner(5), Wilson H. Miller(5), LeeAnn Ramsay(5), Dan Moldoveanu(5), Catalin Mihalcioiu(5), Jennifer A. Wargo(4), Michael A. Davies(4), April A. N. Rose(4), Meriem Messaoudene(4), Corentin Richard(4), Arielle Elkrief(4), Matthew G. Annis(4), Chang‐Jiun Wu(4), Li Li(3)